We may earn a commission if you buy through this link, at no extra cost to you.
NAD+ is the most-asked-about item in this vendor's catalog and the only one that isn't a peptide. Here's the record, in plain English.
We may earn a commission if you buy through this link, at no extra cost to you.
Research use only · not for human consumption · not medical advice.
Nicotinamide adenine dinucleotide. A small molecule in every living cell that shuttles energy and is used by enzymes involved in DNA repair and metabolism. Your body makes it from vitamin B3 and related molecules. Levels in tissue decline with age — that observation is the reason for the interest.
It is not a peptide. Peptides are chains of amino acids. NAD+ is a nucleotide — chemically a cousin of the building blocks of DNA. It appears in peptide catalogs because the same vendors sell it.
The vendor's listing: NAD+ 1000 mg, $200 (30 Aug 2026 catalog). Lot documentation → No NAD+ lot was among the 10 we checked — request one below.
Infused NAD+ (the form research vendors sell). A September 2026 review found five human studies in total: an 8-person open-label infusion study, an 11-person pharmacokinetic study with saline control, a 10-person safety study of infused NMN, one Parkinson's case report, and a 14-person retrospective comparison. What they measured: NAD+ levels in blood, oxidative-stress and inflammation markers, self-reported sleep. What they did not measure: any health outcome over time.
Oral precursors (NR, NMN) — a different product. Several small placebo-controlled trials show that swallowing a precursor raises blood NAD+ and is tolerated over weeks. They are not evidence about infused NAD+, and they measured blood levels, not health outcomes.
Reported in the small infusion studies: nausea, cramping, flushing and chest discomfort during infusion; no serious events reported in those studies. Long-term safety data: none.
Regulatory status (as of Sep 2026 — re-verified quarterly). Not an approved drug. FDA lists "Nicotinamide Adenine Dinucleotide (NAD)" as a 503A Category 1 substance — "under evaluation" for pharmacy compounding, which is the status that lets licensed clinics offer it while FDA decides. It does not appear on FDA's compounding safety-risk page. That is a materially different position from the peptides on this site, most of which sit in "nominated but withdrawn." WADA: not named on the Prohibited List as far as we found.
Unknown: whether raising blood NAD+ changes anything that matters in a person; whether infused NAD+ even reaches cells intact; what a research-grade vial contains versus a pharmacy preparation.
| Check | What "pass" looks like |
|---|---|
| Identity | The lab names the molecule (β-NAD, often as the disodium salt) — not just "NAD+" |
| Purity + method | A number with a method (HPLC) per lot. NAD+ degrades; the reported date matters more than usual |
| Net content | Milligrams actually in the vial vs the 1000 mg label |
| Endotoxin | Per lot with method, if claimed |
| Lot ID | Vial lot matches the COA lot field |
| Lab lookup | The search code resolves at the lab and the PDF matches |
We may earn a commission if you buy through this link, at no extra cost to you.
| id | title | type | date | why | bias | status |
|---|---|---|---|---|---|---|
| S1 | Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine — Alkhodairy et al., Frontiers in Aging | lit | 2026-09-10 | Counts and characterizes every human IV study; quoted above | Academic review | verified — read |
| S2 | A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ — Grant et al., Front Aging Neurosci | lit | 2019 | The controlled pharmacokinetic study (n=11) | Academic; NAD-research nonprofit involvement | verified (URL) — not yet read |
| S3 | Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults — Martens et al., Nat Commun | lit | 2018 | Oral precursor RCT: blood levels, tolerability | Academic; industry-supplied product | verified (URL) — not yet read |
| S4 | Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — FDA category lists | regulator | updated 2026-05-14 | NAD in Category 1 | Regulator | verified |
| S5 | Certain Bulk Drug Substances … Significant Safety Risks — FDA | regulator | page current 2026-04-22 | NAD absent from this page | Regulator | verified |
| S6 | The Prohibited List — WADA | regulator | current edition | Absence check | Regulator | verified (URL) — current PDF not yet opened |
| S7 | Peptide Restore NAD+ listing | vendor-doc | catalog 2026-08-30 | Price, size | Vendor | read 2026-08-30 — catalog page, not linked |
Paste a product link or a lot number. We pull the lab report, look it up at the lab, and reply personally within 48 hours with the three lights. Any vendor. Research use only.
What each document proves, what it doesn't, and where to find it. Research use only.
We may earn a commission if you buy through this link, at no extra cost to you.